MedC Biopharma Partners with A2W Pharma to develop Cannabinoid Therapeutics

Bringing next-gen cannabinoid therapeutics to cancer patients ONTARIO, June 21, 2022 /PRNewswire/ — MedC Biopharma today announced a partnership with A2W Pharma of Malta in the development of MedC’s proprietary novel cannabinoid formulations for the treatment of various cancer-related…